- FoI Number
- 2023-596
- Subject
- Biologic Products
- Date Received
- 08/01/2024
- Request and Response
-
- Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs?
- Abatacept [Orencia] <5
- Adalimumab [Humira] <5
- Adalimumab Biosimilars 31
- Apremilast [Otezla] 0
- Baricitinib [Olumiant] 0
- Bimekizumab [Bimzelx] 0
- Certolizumab [Cimzia] 0
- Etanercept [Enbrel] <5
- Etanercept Biosimilars 16
- Filgotinib [Jyseleca] 0
- Golimumab [Simponi] <5
- Guselkumab [Tremfya] 0
- Infliximab [Remicade] 0
- Infliximab Biosimilars <5
- Ixekizumab [Taltz] 0
- Risankizumab [Skyrizi] 0
- Rituximab [MabThera] <5
- Rituximab Biosimilars 0
- Sarilumab [Kevzara] 0
- Secukinumab [Cosentyx] <5
- Tocilizumab [Ro Actemra] <5
- Tocilizumab Biosimilars 0
- Tofacitinib [Xeljanz] <5
- Upadacitinib [Rinvoq] 0
- Ustekinumab [Stelara] 0
Where we have given <5 answers, this is because NHS Shetland considers that providing more specific information carries a high risk of identifying individuals. As such and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38(1)(b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.
- Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs?
In accordance with FOISA s 17(1), NHS Shetland confirms that it does not hold the information requested. It is not possible to differentiate diagnosis as we do not have access to this data.
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Golimumab [Simponi]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Secukinumab [Cosentyx]
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
